Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-11-26
2011-10-18
Fetterolf, Brandon (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
08039456
ABSTRACT:
The present invention provides a method of stimulating the motility of the gastrointestinal system in a subject in need thereof, wherein the subject suffers from maladies (i.e., disorders, diseases, conditions, or drug- or surgery-induced dysfunction) of the gastrointestinal system, by administering to the subject a ghrelin mimetic, or pharmaceutically acceptable salt thereof. The invention also provides a method of treating a gastrointestinal malady by co-administering a ghrelin mimetic with a laxative, a H2receptor antagonist, a serotonin receptor agonist, pure or mixed, an antacid, an opioid antagonist, a proton pump inhibitor, a motilin receptor agonist, dopamine antagonist, a cholinergic agonist, a cholinesterase inhibitor, somatostatin, octreotide, or any combination thereof.
REFERENCES:
patent: 6451806 (2002-09-01), Farrar
patent: 2002/0042419 (2002-04-01), Hakkinen
patent: 2005/0277677 (2005-12-01), Heiman et al.
patent: 2007/0021331 (2007-01-01), Fraser et al.
patent: 2007/0191283 (2007-08-01), Polvino
patent: 2007/0191289 (2007-08-01), Fushimi et al.
patent: 0657428 (1995-06-01), None
patent: 1159964 (2001-12-01), None
patent: WO 01/34593 (2001-05-01), None
Vippagunta et al, ‘Crystalline solids’ Advanced Drug Delivery Reviews, vol. 48, p. 3-26, 2001.
Bastin et al ‘Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities’ Organic Process Research and Development, vol. 4, p. 427-435, 2000.
Supplementary European Search Report dated Jul. 22, 2010 in EP Application 08742733.2.2123 (PCT/US08/004640).
Liu, Y-L et al., “Ghrelin alleviates cancer chemotherapy-associated dyspepsia in rodents,” Cancer Chemotherapy and Pharmacology, vol. 58, No. 3, pp. 326-333, Sep. 2006.
Rudd, John A. et al., “Anti-emetic activity of ghrelin in ferrets exposed to the cytotoxic anti-cancer agent cisplatin,” Neuroscience Letters, vol. 392, No. 1-2, pp. 79-83, Jan. 9, 2006.
Paul, Bernhard J. et al., “A Practical Synthesis of the Pseudotripeptide RC-1291,” Organic Process Research & Development, vol. 10, No. 2, pp. 339-345, 2006.
Yang, L., et al., “1-[2-(R)-(2-amino-2-methylpropionylamino)-3-(1H-indol-3-yl)propionyl]-3-benzylpiperidine-3(S)-carboxylic acid ethyl ester (L-163,540): a potent, orally bioavailable, and short-duration growth hormone secretagogue,” Journal of Medicinal Chemistry, vol. 41, No. 14, pp. 2439-2441, Jul. 2, 1998.
Peeters et al.,Old and new targets for prokinetic drugs: motilin and ghrelin receptors, Eu Rev Med Pharmacol Sci 2008: 12(Suppl 1): 136-137.
Cordido et al.,Ghrelin and Growth Hormone Secretagogues, Physiological and Pharmacological Aspect, Current Drug Discovery Technologies, 2009, 6, 34-42.
Suchitra et al.,Relative efficacy of some prokinetic drugs in morphine-induced gastrointestinal transit delay in mice, World J. Gastroenterol 2003;9(4): 779-783.
Ohno et al.,The Roles of Motilin and Ghrelin in Gastrointestinal Motility, International Journal of Peptides, vol. 2010, Article ID 820794, 6 pages.
Aerssens et al., The rat lacks functional genes for motilin and for the motilin erceptor, Neurogastroenterology & Motility, vol. 16, p. 841 (2004).
Charoenthongtrakul et al.,Enhanced Gastrintestinal Motility with Orally Active Ghrelin Receptor Agonists, The Journal of Pharmacology and Experimental Therapeutics 329:1178-1186 (2009).
Meerveld et al.,Preclinical studies of opioids and opioid antagonists on gastrointestinal function, Neurogastroenterol Motil (2004) 16 (Suppl 2), 46-53).
De Winter, et al. “Effect of ghrelin and growth hormone-releasing peptide 6 on septic ileus in mice,”Neurogastroenterol Motil, vol. 16, pp. 439-446 (2004).
Supplementary European Search Reported dated Jul. 23, 2010 in EP Application 05786631.1 (PCT/US2005/028851).
Szarka, et al. “Methods for measurement of gastric motility,”Am J Physiol Gastrointest Liver Physiol, vol. 296, pp. G461-G475 (2009).
Glilson, Sharon, Gastrointestinal motility disorders, About.com Guide Updated Jun. 8, 2006. Printed Sep. 24, 2010. http://heartburn.about.com/cs/causes/a/gastro—motility.htm.
Mann William R.
Nelson Richard
Polvino William J.
Arnall Golden & Gregory LLP
Fetterolf Brandon
Helsinn Therapeutics (U.S.), Inc.
Stone Christopher R
Sullivan Clark G.
LandOfFree
Method of stimulating the motility of the gastrointestinal... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of stimulating the motility of the gastrointestinal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of stimulating the motility of the gastrointestinal... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4264483